Targeted stent use in clinical practice based on evidence from the BAsel Stent Cost Effectiveness Trial (BASKET)

Aim It is unknown which patients benefit most from drug-eluting stents (DES) against bare-metal stents (BMS) in a long-term clinical outcome. Methods and results To address this question, data from 826 consecutive patients with angioplasty, randomized 2:1 to DES vs. BMS, with an 18-month follow-up f...

Full description

Saved in:
Bibliographic Details
Published in:European heart journal 2007-03, Vol.28 (6), p.719-725
Main Authors: Rocca, Hans-Peter Brunner-La, Kaiser, Christoph, Pfisterer, Matthias
Format: Article
Language:English
Subjects:
Biological and medical sciences
Blood Vessel Prosthesis
Cardiology. Vascular system
Coronary heart disease
Coronary Restenosis - economics
Coronary Restenosis - prevention & control
Cost-Benefit Analysis
Death, Sudden, Cardiac - prevention & control
Disease-Free Survival
Diseases of the cardiovascular system
Female
Heart
Humans
Male
Medical sciences
Middle Aged
Multivariate Analysis
Myocardial Infarction - economics
Myocardial Infarction - mortality
Myocardial Infarction - therapy
Myocardial Revascularization - economics
Myocardial Revascularization - methods
Myocardial Revascularization - mortality
Prosthesis Failure
Radiotherapy. Instrumental treatment. Physiotherapy. Reeducation. Rehabilitation, orthophony, crenotherapy. Diet therapy and various other treatments (general aspects)
Stents - economics
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Aim It is unknown which patients benefit most from drug-eluting stents (DES) against bare-metal stents (BMS) in a long-term clinical outcome. Methods and results To address this question, data from 826 consecutive patients with angioplasty, randomized 2:1 to DES vs. BMS, with an 18-month follow-up for cardiac death/myocardial infarction (MI) and non-MI-related target-vessel revascularization (TVR) were analysed for interactions between stent type and patient/vessel characteristics predicting events. Rates of 18-month TVRs were lower with DES vs. BMS use (7.5 vs. 11.6%, P = 0.05), but similar for both stents regarding cardiac death/MI (DES, 8.4%; BMS, 7.5%; P = 0.70). Significant interactions between stent type and two multivariable event predictors were identified: small stents (
ISSN:0195-668X
1522-9645
DOI:10.1093/eurheartj/ehl490